CR CRL Charles River Laboratories International, Inc. 로딩 중... : 애널리스트의 강세 및 약세 의견

Charles River signals plans to pursue additional mergers and acquisitions by adding new.

Charles River Laboratories raises its full-year profit forecast and guidance.

IQVIA disclosed a new customer segment breakdown, with EVP (emerging biopharma) being a much larger part of revenue (35%) than previously disclosed, positioning them as the largest EVP provider. — Signals potential re-rating of IQVIA's growth vs. peers, as EVP segment is growing 2-3x faster than large pharma, suggesting structural advantage over other CROs.

Management reaffirmed all guidance, acknowledging a challenged start but pointing to a significant margin expansion in the second half driven by acquisitions, divestitures, and cost savings. The tone is cautiously optimistic about demand recovery, but the full-year outlook remains unchanged, pointing to a neutral stance.

작성자는 현재 반도체 열풍을 코로나 시대의 바이오파마 버블과 비교하며, 혁신의 과도한 추정이 막대한 손실을 초래했다고 경고하고.

작성자는 현재 반도체 열풍을 코로나 시대의 생명과학 버블과 비교하며, 과장된 가정이 유사한 붕괴로 이어질 수 있다고 경고합니다.

매도측 은행의 상당한 목표 주가 하향은 회사의 펀더멘털 또는 밸류에이션에 대한 전망 악화를 의미합니다.

Despite continued revenue decline in 2026, management sees demand stabilization and is guiding to margin expansion, implying a trough and turnaround story for 2026.

IQVIA noted that cancellations in Q4 were 'slightly above the normal range' due to idiosyncratic reasons, but overall demand metrics (pipeline, RFP flow, win rates) improved, and backlog reached a record high. — Despite a slightly elevated cancellation rate, the strong bookings and growth in backlog indicate a healthy overall demand environment for clinical research services, a positive signal for the whole CRO sector.